Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

KPRX

Kiora Pharmaceuticals Inc

Sep 20 • 04:00PM ET

3.66

Dollar change -0.06
Percentage change -1.56	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-7.70	Insider Own	10.42%	Shs Outstand	2.97M	Perf Week	0.00%
Market Cap	10.87M	Forward P/E	-	EPS next Y	-2.23	Insider Trans	7.76%	Shs Float	2.66M	Perf Month	-10.95%
Income	2.67M	PEG	-	EPS next Q	-0.76	Inst Own	47.86%	Short Float	0.22%	Perf Quarter	-1.61%
Sales	16.02M	P/S	0.68	EPS this Y	103.87%	Inst Trans	6.03%	Short Ratio	0.19	Perf Half Y	-30.28%
Book/sh	11.14	P/B	0.33	EPS next Y	-338.08%	ROA	10.54%	Short Interest	0.01M	Perf Year	-26.06%
Cash/sh	9.37	P/C	0.39	EPS next 5Y	-	ROE	13.69%	52W Range	3.00 - 8.98	Perf YTD	-22.15%
Dividend Est.	-	P/FCF	2.29	EPS past 5Y	56.98%	ROI	8.05%	52W High	-59.25%	Beta	-0.28
Dividend TTM	-	Quick Ratio	19.22	Sales past 5Y	-27.40%	Gross Margin	99.47%	52W Low	22.00%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	19.22	EPS Y/Y TTM	92.19%	Oper. Margin	39.28%	RSI (14)	49.67	Volatility	7.29% 5.94%
Employees	12	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	16.66%	Recom	1.00	Target Price	30.33
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	92.55%	Payout	-	Rel Volume	0.40	Prev Close	3.72
Sales Surprise	-	EPS Surprise	38.13%	Sales Q/Q	-	Earnings	Aug 09 BMO	Avg Volume	31.83K	Price	3.66
SMA20	1.37%	SMA50	-5.70%	SMA200	-23.20%	Trades		Volume	12,712	Change	-1.56%

Aug-09-24 02:53PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies (Newsfile)
Aug-06-24 07:03AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Jul-30-24 06:45AM	Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies (Newsfile)
Jul-10-24 07:00AM	Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation (Newsfile)
06:54AM	Loading…
Jul-01-24 06:54AM	Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jun-25-24 06:45AM	Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile)
Jun-18-24 09:40AM	Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? (Zacks)
May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile) -6.36%
May-20-24 07:00AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
May-10-24 01:54PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease (Newsfile)
May-08-24 07:00AM	Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference (Newsfile)
May-06-24 07:00AM	Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa (Newsfile)
Apr-11-24 07:00AM	Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study (Newsfile)
07:00AM	Loading…
Apr-05-24 07:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Mar-28-24 06:45AM	Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting (Newsfile) +14.41%
Mar-25-24 07:00AM	Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases (Newsfile)
Mar-08-24 07:00AM	Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye (Newsfile)
Feb-01-24 08:14AM	Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today? (InvestorPlace) +53.87%
Jan-31-24 06:40PM	Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million (Newsfile) -6.20%
05:15PM	Kiora Pharmaceuticals and Th a Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties (Newsfile)
Nov-17-23 01:54PM	Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301 (News Direct)
Nov-09-23 07:18AM	Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa (Newsfile)
Nov-04-23 12:15PM	AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa (Newsfile)
Oct-16-23 07:00AM	Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference (Newsfile) -5.30%
Oct-03-23 07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa (Newsfile)
Sep-21-23 07:00AM	Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years (Newsfile)
Sep-18-23 07:00AM	Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa (Newsfile)
Sep-14-23 07:01AM	Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa (Newsfile)
07:00AM	Loading…
Sep-01-23 07:00AM	Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 (Newsfile)
Aug-29-23 01:43PM	Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases (Newsfile)
Aug-23-23 07:33PM	Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis (GuruFocus.com) +22.55% -16.80%
07:00AM	Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis (Newsfile)
Aug-22-23 01:06PM	Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program (Newsfile)
Aug-16-23 07:00AM	Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (Newsfile)
Aug-08-23 07:00AM	Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress (Newsfile)
Aug-03-23 07:00AM	Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment (Newsfile)
Aug-01-23 07:00AM	Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jul-05-23 07:00AM	Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease (Newsfile)
Jun-23-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -6.57%
Jun-20-23 10:58AM	Life Science Investor Forum Agenda Announced for June 22nd (GlobeNewswire) -7.68%
Jun-15-23 07:00AM	Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 (Newsfile) +5.49%
Jun-14-23 08:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Jun-06-23 04:30PM	Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile) -7.53%
Jun-02-23 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering (Newsfile) -49.55%
May-09-23 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments (Newsfile)
May-01-23 07:00AM	Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting (Newsfile) -10.36%
Apr-27-23 02:55PM	Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind (Newsfile) +8.90%
Apr-26-23 07:00AM	Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects (Newsfile) +6.98%
Apr-21-23 07:00AM	Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile) +14.49%
Apr-17-23 07:00AM	Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Mar-30-23 07:00AM	Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting (Newsfile)
Mar-23-23 07:00AM	Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress (Newsfile) -9.37%
Mar-10-23 07:00AM	Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting (Newsfile)
Feb-09-23 12:00PM	Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update (Zacks)
Feb-07-23 08:00AM	Kioras stock rallies as eye drop treatment moves into mid-stage clinical trial (MarketWatch) +38.72%
07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Feb-03-23 07:00AM	Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital (Newsfile)
Jan-09-23 07:00AM	Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website (Newsfile)
Jan-03-23 07:01AM	Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023 (Newsfile)
Dec-14-22 08:19AM	Stonegate Healthcare Reviews Retinitis Pigmentosa (Newsfile)
Nov-18-22 08:30AM	Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants (Newsfile) -35.85%
Nov-17-22 06:45AM	Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa (Newsfile)
Nov-09-22 06:45AM	Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End (Newsfile) -5.76%
Oct-31-22 08:01AM	KOL Webinar on Genetic Blindness Points to Promise of Kioras Pioneering Solution--Clinical Data in Q1 (News Direct)
Oct-17-22 08:00AM	Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease (Newsfile)
Oct-13-22 06:45AM	Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (Newsfile)
Sep-28-22 11:44AM	Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D. (Newsfile) +6.06%
Sep-26-22 06:45AM	Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split (Newsfile) -10.05%
Sep-13-22 06:45AM	Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance (Newsfile) +21.00%
Aug-15-22 06:30AM	KPRX: What a difference a year makes! (Zacks Small Cap Research)
Aug-12-22 06:45AM	Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results (Newsfile) -10.71%
Jul-28-22 06:45AM	Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics (Newsfile)
Jul-26-22 04:38PM	Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile)
Jul-22-22 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering (Newsfile) -39.76%
Jul-05-22 06:45AM	Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects (Newsfile)
Jun-27-22 06:53AM	Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa (Newsfile)
May-31-22 04:30PM	Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) (Newsfile) +10.00% -5.41%
Apr-25-22 06:45AM	Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022 (Newsfile)
Apr-15-22 09:00AM	Kiora Pharmaceuticals Reports 2021 Results and Provides Business Update (Newsfile)
Mar-21-22 06:45AM	Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30th (Newsfile)
Mar-18-22 12:00PM	Kiora Pharma Snags Orphan Drug Tag For Inherited Genetic Eye Disease Candidate (Benzinga) -7.09%
06:45AM	Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP) (Newsfile)
Feb-08-22 06:45AM	Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference (Newsfile)
Feb-01-22 06:45AM	Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board (Newsfile)
Jan-05-22 07:00AM	Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference (Newsfile) -7.96%
Dec-15-21 07:00AM	Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors (Newsfile) -27.02%
Dec-14-21 07:15AM	Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease (Newsfile) -8.89%
Nov-15-21 07:30AM	Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stengone Carmine N.	Director	Sep 11 '24	Buy	3.68	1,250	4,600	1,250	Sep 12 06:32 AM
Shapiro Aron	Director	Sep 10 '24	Buy	3.60	3,000	10,800	3,000	Sep 11 07:02 AM
Walters-Hoffert Lisa	Director	Aug 19 '24	Buy	3.86	1,250	4,825	1,250	Aug 20 01:00 PM
TYLE PRAVEEN	Director	Aug 19 '24	Buy	3.96	5,000	19,800	5,014	Aug 19 03:45 PM
Tosca Melissa	CFO	Aug 14 '24	Buy	3.21	2,000	6,420	13,599	Aug 15 04:17 PM
Tosca Melissa	EVP Finance	Jun 14 '24	Buy	5.25	100	525	3,979	Jun 14 04:47 PM
Daniels Eric Joseph	Chief Development Officer	Jun 14 '24	Buy	5.29	1,431	7,570	11,222	Jun 14 03:40 PM
Parsons Erin	Director	Jun 13 '24	Buy	4.88	5,260	25,669	5,260	Jun 13 03:51 PM
Strem Brian M.	President and CEO	Jun 13 '24	Buy	5.00	3,000	14,997	14,531	Jun 13 03:49 PM

Open in Screener

FLUX

Flux Power Holdings inc

Sep 20 • 04:00PM ET

3.01

Dollar change -0.06
Percentage change -1.95	%

Industrials • Electrical Equipment & Parts • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

FLUX Flux Power Holdings inc daily Stock Chart

Held by: FORH VTI VXF IWC CCSO

Index	-	P/E	-	EPS (ttm)	-0.43	Insider Own	26.16%	Shs Outstand	16.46M	Perf Week	-8.23%
Market Cap	50.21M	Forward P/E	-	EPS next Y	-	Insider Trans	-3.48%	Shs Float	12.32M	Perf Month	-10.68%
Income	-7.04M	PEG	-	EPS next Q	-	Inst Own	35.78%	Short Float	1.29%	Perf Quarter	-4.44%
Sales	63.85M	P/S	0.79	EPS this Y	-	Inst Trans	3.63%	Short Ratio	2.03	Perf Half Y	-26.23%
Book/sh	0.33	P/B	9.23	EPS next Y	-	ROA	-19.02%	Short Interest	0.16M	Perf Year	-30.96%
Cash/sh	0.07	P/C	40.17	EPS next 5Y	-	ROE	-91.93%	52W Range	2.64 - 5.86	Perf YTD	-26.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	31.08%	ROI	-99.46%	52W High	-48.63%	Beta	1.18
Dividend TTM	-	Quick Ratio	0.42	Sales past 5Y	63.65%	Gross Margin	27.43%	52W Low	14.02%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	1.10	EPS Y/Y TTM	13.39%	Oper. Margin	-8.44%	RSI (14)	42.00	Volatility	6.85% 7.77%
Employees	133	Debt/Eq	2.98	Sales Y/Y TTM	-2.19%	Profit Margin	-11.03%	Recom	1.00	Target Price	9.00
Option/Short	Yes / Yes	LT Debt/Eq	0.31	EPS Q/Q	-77.33%	Payout	-	Rel Volume	1.16	Prev Close	3.07
Sales Surprise	-6.73%	EPS Surprise	-72.97%	Sales Q/Q	-4.18%	Earnings	May 09 AMC	Avg Volume	78.45K	Price	3.01
SMA20	-5.18%	SMA50	-12.03%	SMA200	-23.04%	Trades		Volume	91,003	Change	-1.95%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-24	Initiated	ROTH MKM	Buy	$10
Feb-04-21	Initiated	Maxim Group	Buy	$30
Oct-12-20	Initiated	ROTH Capital	Buy	$13

Sep-12-24 08:31AM	Flux Power Announces Strategic Partnership with Leading Forklift OEM to Launch Private Label Battery Program (Business Wire) +11.22%
Sep-05-24 04:01PM	Flux Power to Write Down $1.7 Million in Obsolete Inventory, Requiring Restatement of Certain Previously Issued Financial Statements (Business Wire) -5.36%
Aug-21-24 08:31AM	Flux Power Expands Commitment to Sustainability with New Partnership for Lithium-ion Battery Recycling (Business Wire)
Jul-16-24 08:31AM	Flux Power Receives OEM-Approval for New L-Series L36-630840 Ah Battery Packs for Class 1 3-Wheel Counterbalance Forklifts (Business Wire)
Jul-09-24 08:31AM	Flux Power to Host Investor Tours at its Lithium-Ion Battery Pack Manufacturing Facility in Vista, California on Wednesday, August 7, 2024 (Business Wire)
08:31AM	Loading…
Jun-11-24 08:31AM	Flux Power to Present at the iAccess Alpha Best Ideas Summer Conference on Tuesday, June 25, 2024 (Business Wire)
May-13-24 11:06AM	Flux Power Holdings, Inc. (NASDAQ:FLUX) Q3 2024 Earnings Call Transcript (Insider Monkey) -5.85%
May-10-24 02:07PM	Flux Power Shares Decline After Fiscal Q3 Results Miss Estimates (MT Newswires) -25.33%
May-09-24 06:10PM	Flux Power Holdings, Inc. (FLUX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.37%
04:05PM	Flux Power Reports Fiscal Year 2024 Third Quarter Financial Results (Business Wire)
Apr-24-24 08:31AM	Flux Power to Host Fiscal Third Quarter 2024 Results Conference Call on Thursday, May 9, 2024 at 4:30 p.m. Eastern Time (Business Wire)
Apr-18-24 04:05PM	Flux Power Appoints Mark Leposky to Board of Directors (Business Wire)
Mar-07-24 08:31AM	Flux Power Unveils New Onboard Integrated Charging Option at MODEX 2024 (Business Wire)
Mar-05-24 08:31AM	Flux Power to Unveil New Battery Pack for Narrow Aisle Forklifts and End Rider/Center Rider Forklifts at MODEX 2024 (Business Wire)
Feb-28-24 08:31AM	Flux Power to Attend the 36th Annual ROTH Conference on March 17-19, 2024 (Business Wire) -11.87%
08:31AM	Loading…
Feb-26-24 08:31AM	Flux Power Appoints Kevin Royal as Chief Financial Officer (Business Wire)
Feb-20-24 08:31AM	Flux Power to Exhibit at MODEX 2024 Tradeshow March 11-14 at the Georgia World Congress Center in Atlanta (Business Wire) +5.66%
Feb-14-24 08:31AM	Flux Power to Present at the Baird 2024 Vehicle Technology & Mobility Conference on February 29, 2024 (Business Wire) +18.72%
Feb-09-24 11:39AM	Flux Power Holdings, Inc. (NASDAQ:FLUX) Q2 2024 Earnings Call Transcript (Insider Monkey) +9.87%
Feb-08-24 05:10PM	Flux Power Holdings, Inc. (FLUX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.64%
04:01PM	Flux Power Reports Fiscal Year 2024 Second Quarter Financial Results (Business Wire)
Jan-31-24 08:31AM	Flux Power to Participate in the Future of Electrification 2024 Virtual Conference on Wednesday, February 7, 2024, at 12:00 PM Eastern Time (Business Wire) -5.95%
Jan-25-24 08:31AM	Flux Power to Host Fiscal Second Quarter 2024 Results Conference Call on Thursday, February 8, 2024 at 4:30 p.m. Eastern Time (Business Wire)
Jan-23-24 02:35PM	Strength Seen in Flux Power Holdings, Inc. (FLUX): Can Its 8.4% Jump Turn into More Strength? (Zacks)
Jan-03-24 08:31AM	Flux Power Issues Shareholder Letter and Corporate Update (Business Wire) +7.33%
Nov-20-23 08:31AM	Flux Power to Attend the Benchmark 12th Annual Discovery One-on-One Conference on December 7, 2023 (Business Wire)
Nov-10-23 03:38PM	Flux Power Holdings, Inc. (NASDAQ:FLUX) Q1 2024 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:01PM	Flux Power Fiscal Year 2024 First Quarter Financial Results (Business Wire)
Nov-03-23 08:30AM	Flux Power Announces Capital Structure Update Including New Credit Facility with Cleveland Capital (Business Wire) +14.20%
Oct-26-23 04:01PM	Flux Power to Host Fiscal First Quarter 2024 Results Conference Call on Thursday, November 9, 2023 at 4:30 p.m. Eastern Time (Business Wire)
09:33AM	Loading…
Sep-27-23 09:33AM	Flux Power Holdings, Inc. (NASDAQ:FLUX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Sep-26-23 01:28PM	Flux Power CEO Ron Dutt discusses explosive growth and AI integration in exclusive interview (News Direct) -5.70%
Sep-21-23 04:01PM	Flux Power Reports Fiscal Full Year 2023 Financial Results (Business Wire) +13.53% -17.58%
Sep-19-23 08:31AM	Flux Power to Showcase the Latest Lithium-Ion Solutions for Electrifying Airport Ground Support Equipment (Business Wire)
Sep-06-23 08:31AM	Flux Power to Host Fourth Quarter and Full Fiscal Year 2023 Results Conference Call on Thursday, September 21, 2023 at 4:30 p.m. Eastern Time (Business Wire)
Aug-30-23 08:31AM	Flux Power to Participate at H.C. Wainwright 25th Annual Global Investment Conference and Lake Street Best Ideas Growth (BIG7) Conference in September (Business Wire) +7.18%
Aug-03-23 08:31AM	Flux Power Closes New $15 Million Credit Facility with Gibraltar Business Capital (Business Wire)
May-31-23 09:16AM	Flux Power Holdings, Inc. Discusses Significant Revenue, Customer Growth with The Stock Day Podcast (Newsfile) -5.61%
May-25-23 08:31AM	Flux Power to Present at LD Micro Invitational XIII Conference on June 6, 2023 (Business Wire)
May-13-23 08:12AM	Flux Power Holdings Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-11-23 05:15PM	Flux Power Holdings, Inc. (FLUX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.50%
04:01PM	Flux Power Reports 3rd Quarter Fiscal 2023 Financial Results (Business Wire)
May-09-23 08:31AM	Flux Power Announces UL Solutions List Status for Next-Generation G2 Series Battery Platform (Business Wire)
Apr-27-23 05:30PM	Flux Power Renews $14 Million Credit Facility with First Citizens Bank (Business Wire) +9.04%
08:31AM	Flux Power to Host Fiscal Third Quarter 2023 Results Conference Call on Thursday, May 11, 2023 at 4:30 p.m. Eastern Time (Business Wire)
Apr-17-23 09:12AM	Flux Power Holdings, Inc. (NASDAQ:FLUX) Might Not Be As Mispriced As It Looks (Simply Wall St.)
Apr-13-23 08:31AM	Flux Power Announces Opening of Strategic Support Center in Atlanta to Accelerate Customer Expansion (Business Wire)
Mar-27-23 09:15AM	Flux Power Holdings, Inc. CEO, Ron Dutt, Discusses Increasing Demand of Lithium-ion Energy Storage Among Fortune 500 Companies with The Stock Day Podcast (Newsfile)
Mar-14-23 08:31AM	Flux Power to Showcase Existing and New Product Lines at ProMat 2023, March 20-23, 2023 (Business Wire) -6.23%
Mar-10-23 07:24AM	Investing in Flux Power Holdings (NASDAQ:FLUX) a year ago would have delivered you a 239% gain (Simply Wall St.) -18.98%
Mar-07-23 08:50AM	Flux Power Holdings, Inc. (FLUX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Feb-16-23 08:31AM	Flux Power to Host Investor and Analyst Tours at its Lithium-Ion Battery Pack Manufacturing Facility in Vista, California on Wednesday, March 15, 2023 (Business Wire)
Feb-15-23 08:50AM	Recent Price Trend in Flux Power Holdings, Inc. (FLUX) is Your Friend, Here's Why (Zacks) +7.61%
Feb-12-23 10:50PM	Flux Power Holdings, Inc. (NASDAQ:FLUX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Feb-11-23 07:04AM	Flux Power Holdings, Inc. (NASDAQ:FLUX) surges 16%; individual investors who own 39% shares profited along with institutions (Simply Wall St.)
Feb-09-23 05:25PM	Flux Power Holdings, Inc. (FLUX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +7.65% +9.05%
04:01PM	Flux Power Reports 2nd Quarter Fiscal 2023 Financial Results (Business Wire)
Jan-25-23 08:31AM	Flux Power to Host Fiscal Second Quarter 2023 Results Conference Call on Thursday, February 9, 2023 at 4:30 p.m. Eastern Time (Business Wire)
Jan-19-23 08:31AM	Flux Power Expands Testing and Product Validation Capabilities with On-Site Vibration Table (Business Wire) -8.35%
Jan-13-23 08:31AM	Flux Power Announces Expanded $14 Million Credit Facility with Silicon Valley Bank (Business Wire)
Jan-10-23 08:46AM	Flux Power Holdings, Inc.'s (NASDAQ:FLUX) Profit Outlook (Simply Wall St.)
Jan-04-23 08:31AM	Flux Power Issues Shareholder Letter and Corporate Update (Business Wire)
Nov-15-22 04:01PM	Flux Power Announces Expanded Executive Role (Business Wire) +5.20%
Nov-10-22 05:15PM	Flux Power Holdings, Inc. (FLUX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.66% +14.01%
04:01PM	Flux Power Reports First Quarter Fiscal 2023 Financial Results (Business Wire)
Oct-25-22 08:31AM	Flux Power to Host Fiscal First Quarter 2023 Results Conference Call on Thursday, November 10, 2022 at 4:30 p.m. Eastern Time (Business Wire) +8.71%
Oct-04-22 08:31AM	Flux Power to Present at MicroCap Rodeo Windy City Roundup Conference (Business Wire) +8.21%
Sep-23-22 10:12AM	Flux Power Pops On Better-Than-Expected Q4 Earnings (Benzinga)
Sep-22-22 04:30PM	Edited Transcript of FLUX.OQ earnings conference call or presentation 22-Sep-22 8:30pm GMT (Thomson Reuters StreetEvents) -7.98%
04:01PM	Flux Power Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Sep-15-22 07:10AM	Flux Power Holdings (NASDAQ:FLUX) adds US$7.2m to market cap in the past 7 days, though investors from three years ago are still down 64% (Simply Wall St.)
Sep-08-22 08:31AM	Flux Power Host Fourth Quarter and Full Fiscal Year 2022 Results Conference Call on Thursday, September 22, 2022 at 4:30 p.m. Eastern Time (Business Wire)
Sep-06-22 08:31AM	Flux Power Announces Record New Purchase Orders of $64 Million in Fiscal Year 2022 (Business Wire) +7.94%
Aug-03-22 07:21AM	When Will Flux Power Holdings, Inc. (NASDAQ:FLUX) Become Profitable? (Simply Wall St.)
Jul-07-22 08:31AM	Flux Power to Host Investor Tours at its Lithium-Ion Battery Pack Manufacturing Facility in Vista, California on Tuesday, August 2, 2022 (Business Wire)
May-18-22 08:31AM	Flux Power to Present at Upcoming Investor Conferences (Business Wire)
May-15-22 08:24AM	Flux Power Holdings, Inc. (NASDAQ:FLUX) Just Reported Earnings, And Analysts Cut Their Target Price (Simply Wall St.)
May-12-22 05:25PM	Flux Power Holdings, Inc. (FLUX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +10.00%
04:01PM	Flux Power Reports Fiscal Third Quarter 2022 Financial Results (Business Wire)
Apr-27-22 08:31AM	Flux Power Host Third Quarter 2022 Results Conference Call on Thursday, May 12, 2022 at 4:30 p.m. Eastern Time (Business Wire)
Apr-08-22 07:00AM	Fluxys Belgium 8 April 2022 13:00 CET - Regulated information: ordinary and extraordinary general meetings on 10 May 2022 (GlobeNewswire)
Mar-30-22 12:30PM	Fluxys Belgium: Regulated information - 2021 results (GlobeNewswire)
08:31AM	Flux Power Launches New High-Capacity Version of Lithium-ion Battery Pack for Walkie Pallet Jacks at MODEX 2022 (Business Wire)
Mar-29-22 08:31AM	Flux Power Unveils New Lithium-ion Battery Pack for AGVs & AMRs at MODEX 2022 (Business Wire)
Mar-28-22 08:31AM	Flux Power Unveils New Lithium-ion Battery Pack for 3-Wheel Forklifts at MODEX 2022 (Business Wire)
Mar-09-22 08:31AM	Flux Power to Participate & Unveil Two New Lithium-Ion Battery Packs at MODEX 2022 on March 28-31, 2022 (Business Wire)
Mar-02-22 08:31AM	Flux Power to Attend the 34th Annual ROTH Conference March 13-15, 2022 (Business Wire) -5.00%
Feb-10-22 05:35PM	Flux Power Holdings, Inc. (FLUX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -13.83%
04:01PM	Flux Power Reports Fiscal Second Quarter 2022 Financial Results (Business Wire)
Feb-07-22 06:38PM	Formidable Asset Management, LLC Buys Flux Power Holdings Inc, BP PLC, BHP Group, Sells Eaton ... (GuruFocus.com) +8.41%
Feb-03-22 03:01PM	Will Flux Power Holdings, Inc. (FLUX) Report Negative Earnings Next Week? What You Should Know (Zacks) -5.17%
Jan-27-22 05:25PM	KLA (KLAC) Q2 Earnings and Revenues Top Estimates (Zacks) -5.36%
Jan-20-22 08:31AM	Flux Power Host Second Quarter 2022 Results Conference Call on Thursday, February 10, 2022 at 4:30 p.m. Eastern Time (Business Wire) -5.18%
Jan-19-22 08:31AM	Flux Power Appoints Cheemin Bo-Linn to its Board of Directors (Business Wire)
Jan-13-22 08:31AM	Flux Power Issues Shareholder Letter and Corporate Update (Business Wire)
Dec-27-21 12:49PM	Winnebago, Xerox, Babcock & Willcox, One Stop Systems and Flux Power highlighted as Zacks Bull and Bear of the Day (Zacks)
Dec-20-21 08:33AM	Do Options Traders Know Something About Flux Power (FLUX) Stock We Don't? (Zacks) -5.07%
Dec-16-21 08:08AM	Flux Power Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program (Business Wire)
Dec-01-21 07:16AM	Top 10 Stock Picks of Hal Mintzs Sabby Capital (Insider Monkey) -5.43%
Nov-12-21 08:08AM	Flux Power Announces Financial Results for First Quarter of FY 2022; Revenue of $6.3M, an Increase of 39% YOY (Business Wire)

Flux Power Holdings, Inc. engages in the design, development, and sale of rechargeable lithium-ion energy storage systems for industrial applications. It focuses on electric forklifts and airport ground support equipment. The company was founded by Christopher L. Anthony and Michael Johnson on September 21, 1998 and is headquartered in Vista, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Johnson Michael	Director	Jun 12 '24	Sale	2.98	134,623	401,500	4,187,934	Jun 14 08:03 PM
Johnson Michael	Director	May 17 '24	Sale	3.32	16,453	54,652	4,322,557	May 21 08:10 PM
Walters-Hoffert Lisa	Director	Apr 29 '24	Sale	4.50	534	2,403	27,050	Apr 30 06:40 PM
Walters-Hoffert Lisa	Director	Apr 22 '24	Sale	4.03	5,909	23,829	26,058	Apr 22 09:56 PM
Scheiwe Charles	CFO and Secretary	Nov 02 '23	Sale	3.29	638	2,102	14,028	Nov 06 06:56 PM
Mason Jeffrey Curtis	Vice President of Operations	Nov 02 '23	Sale	3.29	389	1,281	2,267	Nov 06 06:54 PM
DUTT RONALD F	CEO and President	Nov 02 '23	Sale	3.29	1,221	4,022	40,430	Nov 06 06:52 PM
DUTT RONALD F	CEO and President	Oct 31 '23	Sale	3.30	582	1,921	41,651	Oct 31 08:52 PM
DUTT RONALD F	CEO and President	Oct 30 '23	Sale	3.30	1,091	3,600	38,213	Oct 30 08:23 PM
DUTT RONALD F	CEO and President	Oct 27 '23	Sale	3.35	333	1,116	39,304	Oct 30 08:23 PM
Scheiwe Charles	CFO and Secretary	Oct 30 '23	Sale	3.30	734	2,422	12,566	Oct 30 08:19 PM
Scheiwe Charles	CFO and Secretary	Oct 27 '23	Sale	3.35	333	1,116	13,300	Oct 30 08:19 PM
Johnson Michael	Director	Sep 28 '23	Sale	3.61	30,000	108,432	4,320,601	Sep 29 07:57 PM
Johnson Michael	Director	Sep 27 '23	Sale	3.65	134	489	4,350,601	Sep 29 07:57 PM
Walters-Hoffert Lisa	Director	Sep 25 '23	Sale	3.88	6,761	26,221	15,084	Sep 25 07:38 PM
Johnson Michael	Director	Sep 21 '23	Sale	4.60	9,202	42,364	4,350,735	Sep 25 07:34 PM

KPRX

Kiora Pharmaceuticals Inc

FLUX

Flux Power Holdings inc

Upgrade your FINVIZ experience